Crushed by PhIII antibiotic flop, PolyPid says it got FDA support for a comeback — by focusing on subgroup

When PolyPid revealed its lead program had flunked the main goal of the first Phase III trial, it underscored positive results from a subgroup analysis. The Israeli biotech, which already had another Phase III underway, said it would talk to the FDA before deciding what to do with the second trial.